Last edition
News about "active pharmaceutical ingredients (APIs)"
Ipca Labs Receives US FDA Form 483 with Three Observations after Tarapur Facility Inspection
The US Food and Drug Administration (US FDA) has completed an inspection of Ipca Laboratories' Active Pharmaceutical Ingredients (APIs) manufacturing plant in Tarapur, Palghar (Maharashtra).
Active Pharmaceutical Ingredients (APIs) | 06/12/2025 | By Dineshwori | 165
CBC India Launches New 'Ingredients & Packaging Solutions' Business at CPHI India 2025
CBC India has unveiled its new ‘Ingredients & Packaging Solutions’ business at CPHI India 2025, marking a major step in its evolution toward offering integrated, end-to-end formulation and packaging support. The new identity strengthens the company’s role as a versatile, future-ready partner for pharma, nutraceutical, and allied sectors.
Active Pharmaceutical Ingredients (APIs) | 27/11/2025 | By Dineshwori
Under this partnership, Antheia will leverage TAPI's next-generation fermentation capabilities and manufacturing facilities in Europe to further commercialise its pipeline of biosynthetic key starting materials (KSMs) and active pharmaceutical ingredients (APIs).
Active Pharmaceutical Ingredients (APIs) | 21/11/2025 | By Dineshwori
Valiant Advanced Sciences Begins Commercial Operations at New Greenfield Facility in Gujarat
According to Valiant Advanced Sciences, the new plant is dedicated to the production of Acetic Anhydride, a key chemical in the Ketene and Diketene derivatives category, serving both domestic and international markets.
Active Pharmaceutical Ingredients (APIs) | 07/11/2025 | By Dineshwori | 141
Cambridge Isotope Laboratories (CIL), a subsidiary of Otsuka Pharmaceutical (Japan), has launched ISOAPI-D, a unified brand of deuterated intermediates for active pharmaceutical ingredient (API) synthesis, at CPhI Frankfurt.
Active Pharmaceutical Ingredients (APIs) | 29/10/2025 | By Dineshwori
USFDA Concludes Inspection at Dr. Reddy's Srikakulam Facility with VAI Classification
Dr. Reddy’s Laboratories has announced that the United States Food and Drug Administration (USFDA) has completed a Good Manufacturing Practice (GMP) and Pre-Approval Inspection (PAI) at its formulations manufacturing facility (FTO 11) in Srikakulam, Andhra Pradesh.
Active Pharmaceutical Ingredients (APIs) | 21/10/2025 | By Dineshwori | 282
Ipca Laboratories Expands Global Footprint with New German Subsidiary
Ipca Laboratories has announced the incorporation of its wholly owned subsidiary, Ipca Pharmaceuticals GmbH, in the Federal Republic of Germany with an initial paid-up capital of Euro 25,000.
Active Pharmaceutical Ingredients (APIs) | 16/10/2025 | By Dineshwori | 185
Aurobindo Pharma Expands Business in Malaysia with New Subsidiary
Aurobindo Pharma has announced the incorporation of a new wholly owned subsidiary, Aurobindo Pharma (Malaysia) SDN. BHD., through its subsidiary Helix Healthcare B.V.
Active Pharmaceutical Ingredients (APIs) | 18/09/2025 | By Dineshwori | 297
FDA Launches 'Green List' to Crack Down on Illegal GLP-1 API Imports
The US Food and Drug Administration (FDA) has created a new “green list” import alert to stop potentially dangerous GLP-1 (glucagon-like peptide-1) active pharmaceutical ingredients (APIs) from unverified foreign sources from entering the US market.
Active Pharmaceutical Ingredients (APIs) | 09/09/2025 | By Dineshwori | 656
India's Push for API Self-Reliance Under the PLI Scheme
India’s Production Linked Incentive (PLI) scheme for bulk drugs and key starting materials is transforming the country’s pharmaceutical manufacturing landscape, pushing the sector toward self-reliance.
Active Pharmaceutical Ingredients (APIs) | 31/08/2025 | By Darshana | 1017
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy